Analyst Expectations For C4 Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on C4 Therapeutics (NASDAQ:CCCC), with recent ratings ranging from bullish to indifferent. The average 12-month price target is now $8.4, down from $10.00, indicating a 16.0% decrease. Analysts from JP Morgan, Stifel, Morgan Stanley, BMO Capital, and HC Wainwright & Co. have made various adjustments to their ratings and price targets. C4 Therapeutics is a biopharmaceutical company with a market cap above industry averages, a revenue growth rate of 63.93%, and strong profitability indicators like net margin and ROE, but a higher debt-to-equity ratio than the industry average.
January 29, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
C4 Therapeutics has received mixed analyst ratings with a downward revision in the average price target to $8.4. The company has strong revenue growth and profitability metrics but a higher debt-to-equity ratio.
The mixed analyst ratings and the decrease in the average price target suggest uncertainty, which could lead to a neutral short-term impact on C4 Therapeutics' stock price. The strong revenue growth and profitability may counterbalance concerns over the higher debt-to-equity ratio. The score is neutral due to these opposing factors.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100